Drug Trial Radar · NCT04355858
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jul 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
319
Planned (sponsor's estimate)
Start
May 1, 2020
Primary completion
May 1, 2023
Study completion Apr 1, 2025
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, single-center, open-label, umbrella-shaped phase II clinical study for patients with HR+/HER2- endocrine-resistant advanced breast cancer.
Conditions
- Breast Cancer
- Metastatic Cancer
Interventions
SHR7390Drug
MEK1/2 inhibitor
FamitinibDrug
Multi-target tyrosine kinase inhibitor
SHR3162Drug
PARP inhibitor
PyrotinibDrug
HER1 / HER2 receptor tyrosine kinase inhibitor
CapecitabineDrug
In Arm III, if the patient had not previously used capecitabine,she would receive pyrotinib and capecitabine, if the patients have previously used capecitabine, she would only used pyrotinib as a single agent.
SHR1210Drug
PD-1 antibody
EverolimusDrug
mTOR inhibitor
Nab paclitaxelDrug
Albumin bound paclitaxel
SHR2554Drug
EZH2 inhibitor
SHR3680Drug
AR inhibitor
SHR6390Drug
CDK4/6 inhibitor
SHR1701Drug
anti-PD-L1/TGF-βRII bifunctional fusion protein
SERDDrug
Fulvestrant
AIDrug
aromatase inhibitor
VEGFiDrug
Bevacizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.